Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 3/2024

01-02-2024 | Amyloidosis

Update on Amyloid Polyneuropathy and Treatment

Authors: Sasha A. Živković, MD, PhD, J. David Avila, MD, Cesia Gallegos-Kattan, MD, MHS, Dianna Quan, MD

Published in: Current Treatment Options in Neurology | Issue 3/2024

Login to get access

Abstract

Purpose of Review

The purpose of this review is to summarize currently available and developing diagnostic and treatment options for hereditary transthyretin amyloid polyneuropathy. Transthyretin amyloidosis (ATTR) predominantly manifests with cardiomyopathy and/or peripheral neuropathy, but amyloid deposits may be found in other organs or tissues.

Recent Findings

Currently available treatments include transthyretin gene silencers (for hereditary ATTR peripheral neuropathy only) and transthyretin stabilizers (tafamidis for ATTR cardiomyopathy in the USA, and for both hereditary ATTR peripheral neuropathy and ATTR cardiomyopathy in Europe, Japan, Brazil, and some other countries), and liver transplantation. Gene silencers stop the progression of hereditary ATTR peripheral neuropathy in most patients, and transthyretin stabilizers reduce hospitalizations and mortality in patients with ATTR cardiomyopathy. The use of liver transplantation for ATTR has declined with the availability of more effective therapies, and shortage of available allografts. On the horizon are new treatments already in clinical trials including new gene silencers and gene editing agents, new transthyretin stabilizers, and amyloid removal treatments.

Summary

Recently approved treatments for ATTR have changed its natural history, and additional medications may get approved in the near future. Early diagnosis is still essential to improve treatment outcomes. New management strategies may include combinations of gene silencers, transthyretin stabilizers, gene editing, and amyloid removal agents, but the cost may become the limiting factor.
Literature
1.
Obici L, Adams D. Acquired and inherited amyloidosis: knowledge driving patients’ care. J Peripher Nerv Syst. 2020;25(2):85–101.PubMedCrossRef
2.
Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–43.PubMedCrossRef
3.
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20.PubMedCrossRef
4.
Wininger AE, Phelps BM, Le JT, Harris JD, Trachtenberg BH, Liberman SR. Musculoskeletal pathology as an early warning sign of systemic amyloidosis: a systematic review of amyloid deposition and orthopedic surgery. BMC Musculoskelet Disord. 2021;22(1):51.PubMedPubMedCentralCrossRef
5.
Wajnsztajn Yungher F, Kim A, Boehme A, Kleyman I, Weimer LH, Maurer MS, et al. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J Peripher Nerv Syst. 2020;25(3):265–72.PubMedCrossRef
6.
Zivkovic S, Soman P, Lacomis D. Late-onset peripheral neuropathy in patients with wild type transthyretin amyloidosis (wtATTR). Amyloid. 2020;27(2):142–3.PubMedCrossRef
7.
Papagianni A, Ihne S, Zeller D, Morbach C, Uceyler N, Sommer C. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Amyloid. 2022;29(1):14–22.PubMedCrossRef
8.
Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.
9.
•• Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. Pivotal study showing efficacy of gene silencing of TTR with patisiran.
10.
•• Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. Pivotal study showing efficacy of gene silencing of TTR with inotersen.
11.
Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid. 2022;29(3):184–9.PubMedCrossRef
12.
Coelho T, Dispenzieri A, Grogan M, Conceicao I, Waddington-Cruz M, Kristen AV, et al. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid. 2023:1–4. online ahead of print
13.
Wang AK, Fealey RD, Gehrking TL, Low PA. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc. 2008;83(11):1226–30.PubMedCrossRef
14.
Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features Brain. 1999;122(Pt 10):1951–62.PubMed
15.
Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9.PubMedPubMedCentralCrossRef
16.
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79–89.PubMedCrossRef
17.
Hens D, Wyers L, Claeys KG. Validation of an artificial intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis polyneuropathy as a key example. J Peripher Nerv Syst. 2023;28(1):79–85.PubMedCrossRef
18.
•• Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675–82. Important study demonstrating natural history of hATTR-PN with rapid progression.
19.
Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Theaudin M, Adam C, et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology. 2018;91(2):e143–52.PubMedCrossRef
20.
Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040–50.PubMedCrossRef
21.
Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22(3):507–15.PubMedCrossRef
22.
Karam C, Dimitrova D, Christ M, Heitner SB. Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis. Neurol Clin Pract. 2019;9(4):309–13.PubMedPubMedCentralCrossRef
23.
Salvalaggio A, Coraci D, Cacciavillani M, Obici L, Mazzeo A, Luigetti M, et al. Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. J Neurol. 2021;268(1):189–98.PubMedCrossRef
24.
Poncelet A, Weiler M, Hegenbart U, Sam G, Schonland S, Purrucker JC, et al. Dual-echo turbo spin echo and 12-echo multi spin echo sequences as equivalent techniques for obtaining T2-relaxometry data: application in symptomatic and asymptomatic hereditary transthyretin amyloidosis as a surrogate disease. Invest Radiol. 2022;57(5):301–7.PubMedCrossRef
25.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.PubMedCrossRef
26.
Wlodarski R, Seibert K, Issa NP, O’Brien-Penney B, Soliven B, Sarswat N, et al. (99m) Technetium-pyrophosphate bone scan: a potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: a preliminary study. Muscle Nerve. 2023;67(2):111–6.PubMedCrossRef
27.
Shouman K, Broski SM, Muchtar E, Pendleton CA, Johnson GB, Tracy J, et al. Novel imaging techniques using (18) F-florbetapir PET/MRI can guide fascicular nerve biopsy in amyloid multiple mononeuropathy. Muscle Nerve. 2021;63(1):104–8.PubMedCrossRef
28.
•• Sousa L, Coelho T, Taipa R. CNS involvement in hereditary transthyretin amyloidosis. Neurology. 2021;97(24):1111–9. Important overview of CNS involvement in hATTR.
29.
Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109–22.PubMedCrossRef
30.
Benson MD, Berk JL, Dispenzieri A, Damy T, Gillmore JD, Hazenberg BP, et al. Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid. 2022;29(1):8–13.PubMedCrossRef
31.
Hill MM, Dasari S, Mollee P, Merlini G, Costello CE, Hazenberg BPC, et al. The clinical impact of proteomics in amyloid typing. Mayo Clin Proc. 2021;96(5):1122–7.PubMedCrossRef
32.
Freeman R, Gonzalez-Duarte A, Barroso F, Campagnolo M, Rajan S, Garcia J, et al. Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages. Ann Clin Transl Neurol. 2022;9(9):1370–83.PubMedPubMedCentralCrossRef
33.
Leonardi L, Adam C, Beaudonnet G, Beauvais D, Cauquil C, Not A, et al. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis. Eur J Neurol. 2022;29(5):1477–87.PubMedCrossRef
34.
Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29 Suppl 1(Suppl 1):S27–35.
35.
• Quan D, Obici L, Berk JL, Ando Y, Aldinc E, White MT, et al. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid. 2023;30(1):49–58. Study demonsrating benefits of early treatment of hATTR-PN for preservation of function.
36.
Ando Y, Adams D, Benson MD, Berk JL, Plante-Bordeneuve V, Coelho T, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143–55.PubMedCrossRef
37.
Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–54.PubMedCrossRef
38.
Brannagan TH 3rd, Berk JL, Gillmore JD, Maurer MS, Waddington-Cruz M, Fontana M, et al. Liver-directed drugs for transthyretin-mediated amyloidosis. J Peripher Nerv Syst. 2022;27(4):228–37.PubMedPubMedCentralCrossRef
39.
Dyck PJB, Gonzalez-Duarte A, Obici L, Polydefkis M, Wiesman JF, Antonino I, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. J Neurol Sci. 2019;405: 116424.PubMedCrossRef
40.
41.
•• Adams D, Tournev IL, Taylor MS, Coelho T, Plante-Bordeneuve V, Berk JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1–9. Phase 3 study demonstrating efficacy of vutrisiran for treatment of hATTR-PN.
42.
• Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47(2):157–62. Important overview of liver transplantation in hATTR.
43.
44.
Moshe-Lilie O, Dimitrova D, Heitner SB, Brannagan TH 3rd, Zivkovic S, Hanna M, et al. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid. 2020;27(4):250–3.PubMedCrossRef
45.
Schmidt HH, Wixner J, Plante-Bordeneuve V, Munoz-Beamud F, Llado L, Gillmore JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22(6):1646–57.PubMedPubMedCentralCrossRef
46.
Razvi Y, Porcari A, Di Nora C, Patel RK, Ioannou A, Rauf MU, et al. Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience. Front Cardiovasc Med. 2022;9:1075806.PubMedCrossRef
47.
Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67.PubMedPubMedCentralCrossRef
48.
Ibrahim M, Saint Croix GR, Lacy S, Fattouh M, Barillas-Lara MI, Behrooz L, et al. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev. 2022;27(2):517–24.PubMedCrossRef
49.
Tschope C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges. J Clin Med. 2022;11(8).
50.
•• Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. pivotal study demonstrating benefits of tafamidis for treatment of ATTR-CM.
51.
Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1): e008193.
52.
Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141(15):1214–24.PubMedPubMedCentralCrossRef
53.
Wardhere A, Bampatsias D, Fine N, Garcia-Pavia P, Grogan M, Kristen AV, et al. Heterogeneous worldwide access and pricing of tafamidis. Amyloid. 2023:1–3. (online ahead of print)
54.
Masri A, Aras M, Falk RH, Grogan M, Jacoby D, Judge DP, et al. Long-term safety and tolerability of acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy: updated analysis from an ongoing phase 2 open-label extension study. ISA 2022; Heidelberg, Germany, 2022. p. 47. (abstract)
55.
Gillmore JD, Judge DP, Cappelli F, Fontana M, al. e. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. ESC 2023; Amsterdam, Netherlands, 2023. (abstract)
56.
Bumma N, Kahwash R, Parikh SV, Isfort M, Freimer M, Vallakati A, et al. Multidisciplinary amyloidosis care in the era of personalized medicine. Front Neurol. 2022;13: 935936.PubMedPubMedCentralCrossRef
57.
Obici L, Callaghan R, Ablett J, Bibiloni C, Bueser T, Conceicao I, et al. Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals. BMJ Open. 2023;13(9): e073130.PubMedPubMedCentralCrossRef
58.
Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553–65.PubMedCrossRef
59.
Olshansky B, Muldowney J. Cardiovascular safety considerations in the treatment of neurogenic orthostatic hypotension. Am J Cardiol. 2020;125(10):1582–93.PubMedCrossRef
60.
Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, Franca MC Jr, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448–58.PubMedCrossRef
61.
Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, et al. Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen. Neurol Ther. 2023;12(1):267–87.PubMedCrossRef
62.
Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236–49.PubMedCrossRef
63.
Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22(2):79–83.PubMedCrossRef
64.
Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, et al. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022;29(2):71–8.PubMedPubMedCentralCrossRef
65.
Takahashi R, Ono K, Shibata S, Nakamura K, Komatsu J, Ikeda Y, et al. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area. J Neurol Sci. 2014;345(1–2):231–5.PubMedCrossRef
66.
Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29 Suppl 1(Suppl 1):S14–26.
67.
• Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502. Important study demonstrating potential benefits of gene editing as a treatment of hATTR.
68.
Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227–35.PubMedCrossRef
69.
Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs. 2023. online ahead of print.
70.
Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail. 2019;25(3):147–53.PubMedCrossRef
71.
Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med. 2023;389(3):239–50.
72.
Maurer MS, Buchholtz K, Engelman MM, Grogan M, Hovingh GK, Kristen AV, et al. NNC6019–0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial. ISA 2022; Heidelberg, Germany, 2022. p. 746–7. abstract
73.
• Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, et al. Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy. N Engl J Med. 2023;388(23):2199–201. Demonstration of antibody-associated removal of ATTR in the heart.
74.
Balanchandran M, Foster S, Jackson J, Richey T, Martin E, Kennel S, et al. Development of novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance. ISA 2022; Heidelberg, Germany, 2022. p. 98–9. abstract
75.
Salvi F, Pastorelli F, Plasmati R, Morelli C, Rapezzi C, Bianchi A, et al. Brain microbleeds 12 years after orthotopic liver transplantation in Val30Met amyloidosis. J Stroke Cerebrovasc Dis. 2015;24(6):e149–51.PubMedCrossRef
76.
Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87(8):773–81.PubMedCrossRef
77.
Takahashi Y, Ohashi N, Takasone K, Yoshinaga T, Yazaki M, Roberts M, et al. CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. Amyloid. 2022;29(3):190–6.PubMedCrossRef
78.
Tsai FJ, Jaeger M, Coelho T, Powers ET, Kelly JW. Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid. Amyloid. 2023;30(3):279–89.PubMedCrossRef
79.
Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, et al. Failure of tafamidis to halt progression of Ala36Pro TTR oculomeningovascular amyloidosis. J Stroke Cerebrovasc Dis. 2018;27(9):e212–4.PubMedCrossRef
80.
Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285–95.PubMedCrossRef
Metadata
Title
Update on Amyloid Polyneuropathy and Treatment
Authors
Sasha A. Živković, MD, PhD
J. David Avila, MD
Cesia Gallegos-Kattan, MD, MHS
Dianna Quan, MD
Publication date
01-02-2024
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 3/2024
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-024-00780-z